World’s First Contact Lens for Allergic Eye Itch Now Available in Canada
FYidoctors announced it has received exclusive Canadian in market assessment access for 2021 to the world’s first and only drug-releasing contact lens for vision correction and allergic eye itch: ACUVUE® Theravision™ with Ketotifen.
The announcement comes following Health Canada granting approval to Johnson & Johnson Vision on the innovative contact lens. ACUVUE® Theravision™ with Ketotifen provides relief for those suffering from seasonal allergies through the use of ketotifen, an H1 histamine receptor antagonist for the prevention of itch associated with eye allergies.
It is estimated that more than 10 million Canadians suffer from seasonal allergies for which eye itch is a common symptom. In addition to irritation, itchy eyes impact vision and can make regular tasks for contact lens wearers troublesome.
“For years, Canadians who use contact lenses and suffer from seasonal allergies had to grin and bear the itch of their contacts or switch to glasses and eye drops. We’re so excited those are no longer the only options,” said Dr. Alan Ulsifer, CEO and Chairman of FYidoctors.
A limited introduction of ACUVUE® Theravision™ with Ketotifen through the FYidoctors network of clinics will assess the product in market in Canada. Full Canada launch through all eligible Johnson & Johnson Vision partners will follow in 2022.
“By bringing forward new eye care technology to help practitioners meet the needs of their patients, we are demonstrating our commitment to change the trajectory of eye health to improve quality of life.” said Ted Lachmansingh, Canadian Business Director, Johnson & Johnson Vision Care division of Johnson & Johnson Inc.
FYidoctors will be making ACUVUE® Theravision™ with Ketotifen available in over 220 locations nation-wide.
Click HERE for the full press release.